Amneal Pharmaceuticals, Inc. (AMRX) P/E Ratio History
Historical price-to-earnings valuation from 2017 to 2025
Loading P/E history...
AMRX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Amneal Pharmaceuticals, Inc. (AMRX) trades at a price-to-earnings ratio of 62.4x, with a stock price of $13.72 and trailing twelve-month earnings per share of $0.22.
The current P/E is 71% below its 5-year average of 213.3x. Over the past five years, AMRX's P/E has ranged from a low of 7.4x to a high of 1225.8x, placing the current valuation at the 55th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, AMRX trades at a 179% premium to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, AMRX commands a significant premium over the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AMRX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
AMRX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $42B | 30.0 | - | +183% | |
| $2B | 36.3 | 4.85 | +1883%Best | |
| $92B | 29.2 | 0.75 | +15% | |
| $44B | 28.7 | - | +87% | |
| $111B | 62.8 | - | -62% | |
| $151B | 19.5 | - | -4% | |
| $277B | 15.4Lowest | 0.73Best | +8% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
AMRX Historical P/E Data (2017–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $12.60 | $0.22 | 56.1x | -74% |
| FY2025 Q3 | $10.01 | $0.01 | 685.6x | +221% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $8.09 | $0.01 | 1225.8x | +475% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $4.22 | $0.03 | 120.9x | -43% |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $4.79 | $0.07 | 69.5x | -67% |
| FY2021 Q3 | $5.34 | $0.09 | 58.7x | -72% | |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $5.12 | $0.06 | 87.4x | -59% |
| FY2020 Q4 | $4.57 | $0.62 | 7.4x | -97% | |
| FY2020 Q3 | Wed Sep 30 2020 00:00:00 GM | $3.88 | $0.41 | 9.5x | -96% |
| FY2018 Q1 | Sat Mar 31 2018 00:00:00 GM | $19.45 | $1.50 | 13.0x | -94% |
| FY2017 Q4 | Sun Dec 31 2017 00:00:00 GM | $16.65 | $1.34 | 12.4x | -94% |
Average P/E for displayed period: 213.3x
See AMRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AMRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AMRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAMRX — Frequently Asked Questions
Quick answers to the most common questions about buying AMRX stock.
Is AMRX stock overvalued or undervalued?
AMRX trades at 62.4x P/E, below its 5-year average of 213.3x. At the 55th percentile of historical range, the stock is priced at a discount to its own history.
How does AMRX's valuation compare to peers?
Amneal Pharmaceuticals, Inc. P/E of 62.4x compares to sector median of 22.3x. The premium reflects expected growth above peers.
What is AMRX's PEG ratio?
AMRX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2017-2025.